| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 9, 2014Comprehensive Clinical Data from Randomized Trials Reviewed
After reviewing updated data and analysis for the Boston Scientific Corporation (NYSE: BSX) WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, the U.S. Food and Drug Administration (FDA)...
-
Dec 11, 2013
The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably by a majority, Yes: 13, No: 1, that the benefits of the...
-
Oct 30, 2013
Boston Scientific Corporation (NYSE:BSX) today announced the first German patient enrolment in the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization, a prospective multicentre...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set...
-
May 9, 2013
Boston Scientific Corporation (NYSE: BSX) reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the WATCHMAN® Left Atrial Appendage (LAA) Closure device was...